Intrathecal therapy for chronic pain: current trends and future needs
- PMID: 24338701
- DOI: 10.1007/s11916-013-0388-x
Intrathecal therapy for chronic pain: current trends and future needs
Abstract
The management of chronic pain continues to pose many challenges to healthcare providers. Intrathecal drug delivery systems (IDDS) provide an effective therapy for patients suffering from chronic pain intractable to medical management. However, the clinical growth of intrathecal therapy continues to face many challenges, and is likely underutilized secondary to its high-complexity and limited reimbursement. The clinical utility of IDDS remains limited by lack of prospective randomized, placebo-controlled studies. In addition, there remains a need to enhance physician knowledge on the pharmacodynamics and pharmacokinetics of intrathecal drug delivery and promote further research into this field and drug delivery modalities. The purpose of this article is to provide a comprehensive review of the determinants of successful intrathecal drug delivery with an emphasis on its use in noncancer pain.
Similar articles
-
Managing intrathecal drug delivery (ITDD) in cancer patients.Curr Pain Headache Rep. 2015 Jun;19(6):20. doi: 10.1007/s11916-015-0488-x. Curr Pain Headache Rep. 2015. PMID: 26021753 Review.
-
Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates.Am J Hosp Palliat Care. 2012 Aug;29(5):388-98. doi: 10.1177/1049909111426134. Epub 2011 Nov 15. Am J Hosp Palliat Care. 2012. PMID: 22089523 Review.
-
Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.Medicine (Baltimore). 2017 Mar;96(11):e6354. doi: 10.1097/MD.0000000000006354. Medicine (Baltimore). 2017. PMID: 28296770 Free PMC article.
-
Intrathecal drug delivery for pain management: recent advances and future developments.Expert Opin Drug Deliv. 2019 Aug;16(8):815-822. doi: 10.1080/17425247.2019.1642870. Epub 2019 Jul 19. Expert Opin Drug Deliv. 2019. PMID: 31305165 Review.
-
[Chronic intrathecal drug administration for the control of intractable pain].Brain Nerve. 2008 May;60(5):509-17. Brain Nerve. 2008. PMID: 18516973 Review. Japanese.
Cited by
-
The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain.J Pain Res. 2022 Dec 6;15:3729-3832. doi: 10.2147/JPR.S386879. eCollection 2022. J Pain Res. 2022. PMID: 36510616 Free PMC article. Review.
-
Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.Neuromodulation. 2016 Jul;19(5):522-32. doi: 10.1111/ner.12392. Epub 2016 Feb 9. Neuromodulation. 2016. PMID: 26856969 Free PMC article. Review.
-
History and present state of targeted intrathecal drug delivery.Curr Pain Headache Rep. 2015;19(2):474. doi: 10.1007/s11916-014-0474-8. Curr Pain Headache Rep. 2015. PMID: 25638694 Review.
-
Programmable intrathecal pumps for the management of chronic pain: recommendations for improved efficiency.J Pain Res. 2014 Oct 3;7:571-7. doi: 10.2147/JPR.S46929. eCollection 2014. J Pain Res. 2014. PMID: 25336986 Free PMC article. Review.
-
Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain.Pharmaceutics. 2023 Aug 5;15(8):2088. doi: 10.3390/pharmaceutics15082088. Pharmaceutics. 2023. PMID: 37631302 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources